Floatz logo

EXEMESTANE

Pain

University of Michigan Rogel Cancer CenterSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Pain cohort.

Asset / SponsorPhaseRating
NEPENTHE
Bursa City Hospital
Phase 4BBB
Tapentadol
Grünenthal GmbH
Phase 4BBB
Oxycodone
The First Affiliated Hospital with Nanjing Medical University
Phase 4BBB
FENTANYL
Aga Khan University
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB

View all 50 →

Same molecule, other indications

EXEMESTANE is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
ER+ Breast CancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →